Literature DB >> 26052935

Association between single nucleotide polymorphisms of upstream transcription factor 1 (USF1) and susceptibility to papillary thyroid cancer.

Qingzhong Yuan1, Qingao Bu1, Guoqiang Li1, Jun Zhang1, Tao Cui1, Rui Zhu1, Dongpo Mu1.   

Abstract

BACKGROUND: Thyroid cancer, predominantly by papillary thyroid cancer (PTC), is a malignant tumour of endocrine system with increasing incidence rate worldwide. Upstream transcription factor 1 (USF1) regulates a variety of biological processes by transactivation of functional genes. In this study, we investigated the association between USF1 polymorphisms and PTC risk. MATERIAL &
METHODS: A total of 334 patients with PTC, 186 patients with benign nodules (BN) and 668 healthy controls were enrolled in our study. Tag-SNPs were identified in Chinese Han in Beijing (CHB) from International HapMap Project Databases. Genomic DNAs were extracted by TaqMan Blood DNA kits. SNPs of USF1 were genotyped by TaqMan SNPs genotyping assay. Odds ratios (OR) and corresponding 95% confidence interval (CI) were used to assess the association between USF1 genetic variants and PTC risk. The statistical analyses were carried out with spss 13.0 software.
RESULTS: Five tag-SNPs were retrieved to capture all the genetic variants of USF1. Among the five tag-SNPs, genetic variants in rs2516838, rs3737787 and rs2516839 have significant association with PTC risk. The rs2516838 polymorphisms dominant model (CG+GG vs CC: OR = 0·71; 95% CI: 0·52-0·97; P = 0·033) and allelic model (C vs G: OR = 0·031; 95% CI: 0·56-0·97; P = 0·031) indicated it may act as a protective factor against PTC. On the contrary, the results of rs3737787 polymorphisms: dominant model (CT+TT vs CC: OR = 1·55; 95%CI: 1·09-2·02; P = 0·001) and allelic model (C vs T: OR = 1·35; 95%CI: 1·10-1·64; P = 0·003), as well as the results of rs2516839 polymorphisms: dominant model (GA+AA vs GG: OR = 1·77; 95%CI: 1·31-2·38; P < 0·001) and allelic model (G vs A: OR = 1·36; 95%CI: 1·13-1·63; P = 0·014), revealed that they may act as risk factors for PTC.
CONCLUSION: In this study, we found the SNPs of rs2516838 (mutant G alleles vs wild C alleles), rs3737787 (mutant T alleles vs wild C alleles) and rs2516839 (mutant A alleles vs wild G alleles) were significantly associated with PTC risk. Further large-scale studies with different ethnicities are still needed to validate our findings and explore the underlying mechanism of USF1 in PTC development.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26052935     DOI: 10.1111/cen.12832

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

1.  Upstream transcription factor 1 prompts malignancies of cervical cancer primarily by transcriptionally activating p65 expression.

Authors:  Wen Wang; Shujuan Yao; Hongjing Jiang; Jing Dong; Xiujuan Cui; Xiangyu Tian; Yanyan Guo; Shiqian Zhang
Journal:  Exp Ther Med       Date:  2018-09-18       Impact factor: 2.447

2.  Suppression of metastasis through inhibition of chitinase 3-like 1 expression by miR-125a-3p-mediated up-regulation of USF1.

Authors:  Ki Cheon Kim; Jaesuk Yun; Dong Ju Son; Ji Young Kim; Jae-Kyung Jung; Jeong Soon Choi; Yu Ri Kim; Ju Kyung Song; Sun Young Kim; Sin Kook Kang; Dae Hwan Shin; Yoon-Seok Roh; Sang-Bae Han; Jin Tae Hong
Journal:  Theranostics       Date:  2018-08-07       Impact factor: 11.556

3.  TUG1 long non-coding RNA enlists the USF1 transcription factor to overexpress ROMO1 leading to hepatocellular carcinoma growth and metastasis.

Authors:  Shihai Liu; Jing Qiu; Weitai He; Chao Geng; Guifang He; Changchang Liu; Duo Cai; Xiangping Liu; Ben Tian; Huazheng Pan
Journal:  MedComm (2020)       Date:  2020-11-26

4.  USF1 defect drives p53 degradation during Helicobacter pylori infection and accelerates gastric carcinogenesis.

Authors:  Lionel Costa; Sébastien Corre; Valérie Michel; Krysten Le Luel; Julien Fernandes; Jason Ziveri; Gregory Jouvion; Anne Danckaert; Nicolas Mouchet; David Da Silva Barreira; Javier Torres; Margarita Camorlinga; Mario Milco D'Elios; Laurence Fiette; Hilde De Reuse; Marie-Dominique Galibert; Eliette Touati
Journal:  Gut       Date:  2019-12-10       Impact factor: 23.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.